Company: LENZ
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001628280-25-016818
Chunk: 18

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: S-3
Chunk 18
---
 together with RACHF and Nexus II, the “RA Funds”) in the Merger as an equityholder of LENZ OpCo, (iv) 54,582 shares of Common Stock subject to warrants to purchase shares of Common Stock held by RACHF that were assumed in the Merger, (v) 10,580 shares of Common Stock subject to warrants to purchase shares of Common Stock held by Nexus II that were assumed in the Merger, (vi) 5,371 shares of Common Stock subject to warrants to purchase shares of Common Stock held by the Account that were assumed in the Merger, (vii) 933,038 shares of Common Stock purchased by RACHF in a private placement, (viii) 64,971 shares of Common Stock purchased by Nexus II in a private placement, and (ix) 9,750 shares of Common Stock subject to options held by Dr. Scheiner exercisable within 60 days of March 12, 2025. RA Capital Management, L.P. is the investment manager for the RA Funds. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. Each of RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the securities held by the RA Funds. RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Zach Scheiner, a principal at RA Capital Management, L.P., is a member of the board of directors of the Company. The principal business address of the persons and entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116.

(4) Consists of (i) 598,203 shares of Common Stock received by Versant Vantage II, L.P. (“Versant Vantage II”) in the Merger as an equityholder of LENZ OpCo, (ii) 1,598,789 shares of Common Stock received by Versant Venture Capital VII, L.P. (“Versant VII”) in the Merger as an equityholder of LENZ OpCo, (iii) 70,534 shares of Common Stock subject to warrants to purchase shares of Common Stock